Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Norbert Hollaender"'
Publikováno v:
Blood. 140:10521-10522
Publikováno v:
Biometrical Journal. 62:658-669
In clinical study reports (CSRs), adverse events (AEs) are commonly summarized using the incidence proportion (IP). IPs can be calculated for all types of AEs and are often interpreted as the probability that a treated patient experiences specific AE
Autor:
Maanasa Gowda, Franco Locatelli, Tommaso Stefanelli, Norbert Hollaender, Shahrukh K. Hashmi, Robert Zeiser, Mary E.D. Flowers, Fitzroy Dawkins, Ronjon Chakraverty, Stephanie J. Lee, Nicola Polverelli, Takanori Teshima, Ron Ram
Publikováno v:
Blood. 136:22-24
BACKGROUND Standard first-line treatment of cGVHD includes systemic corticosteroids; however, about 50% of patients (pts) are steroid refractory or dependent (SR/D) and require additional treatment. The best second-line therapy option has not yet bee
Autor:
Norbert Hollaender, Ronjon Chakraverty, Maanasa Gowda, Franco Locatelli, Stephanie J. Lee, Ron Ram, Tommaso Stefanelli, Shahrukh K. Hashmi, Takanori Teshima, Peter Langmuir, Nicola Polverelli, Robert Zeiser
Publikováno v:
Web of Science
Autor:
Antonis Kattamis, Norbert Hollaender, Noppadol Siritanaratkul, Elena Cassinerio, Aurelio Maggio, Stefano Rivella, Bruyère Mahuzier, Ali T. Taher, Yesim Aydinok, Zeynep Karakas, Brian Gadbaw
Publikováno v:
Blood. 131:263-265
In beta-thalassemia, the mechanism driving ineffective erythropoiesis (IE) is insufficiently understood. We analyzed mice affected by beta-thalassemia and observed, unexpectedly, a relatively small increase in apoptosis of their erythroid cells compa
Publikováno v:
Statistics in Medicine. 30:1618-1627
Traditional phase III non-inferiority trials require compelling evidence that the treatment vs control effect bfθ is better than a pre-specified non-inferiority margin θ(NI) . The standard approach compares this margin to the 95 per cent confidence
Autor:
Brian Gadbaw, Moshe Yeshurun, Robert Zeiser, Patricia Delaite, Stephen Ronan Foley, Franco Locatelli, Edric Atienza, Norbert Hollaender, Ron Ram, Takanori Teshima, Andrew S. Artz
Publikováno v:
Biology of Blood and Marrow Transplantation. 24:S208
Autor:
Bruyère Mahuzier, Zeynep Karakas, Yesim Aydinok, Ali T. Taher, Brian Gadbaw, Antonis Kattamis, Noppadol Siritanaratkul, Aurelio Maggio, Norbert Hollaender, Elena Cassinerio
Publikováno v:
Blood. 128:852-852
BACKGROUND: Ruxolitinib (RUX) is approved in adult patients (pts) with myelofibrosis (MF), and in pts with polycythemia vera (PV) who are resistant/intolerant to hydroxyurea. Splenomegaly, a key clinical feature in advanced MF/PV, is also common in p
Autor:
Andrew M. Stein, Norbert Hollaender, Wenping Wang, Ovidiu Chiparus, Hyewon Kim, Robert J. Motzer, Alison A Carter, C. Sarr
Publikováno v:
BMC Cancer
BMC Cancer, Vol 12, Iss 1, p 311 (2012)
BMC Cancer, Vol 12, Iss 1, p 311 (2012)
Background The phase 3 RECORD-1 trial (NCT00410124) established the efficacy and safety of everolimus in patients with metastatic renal cell carcinoma (mRCC) who progress on sunitinib or sorafenib. In RECORD-1, patients received 10 mg everolimus dail
Autor:
David Cella, Jean-Francois Baladi, Andrea Kay, Zeeshan Butt, Tomas Haas, Norbert Hollaender, Jennifer L. Beaumont, Robert J. Motzer
Publikováno v:
The oncologist. 16(5)
Purpose. A phase III, randomized, double-blind, placebo-controlled trial was conducted in patients with metastatic renal cell carcinoma. The focus of this paper is to evaluate the patient-reported outcomes. Methods. Patients were randomly assigned (2